HIKAL vs PPLPHARMA: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. HIKAL shows a higher dividend yield, faster revenue growth and a higher net margin, while PIRAMAL PHARMA shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HIKAL leads 6; PPLPHARMA leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| Live Price | ₹222.3 | ₹214.22 |
| Day Change | -7.51% | -0.13% |
| Volume | 53.59 L | 26.18 L |
| 52-Week High | ₹282.7 | ₹220.36 |
| 52-Week Low | ₹146.25 | ₹132.3 |
| Distance from 52W High | -21.37% | -2.79% |
Valuation
| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| Market Cap | ₹2,740 Cr | ₹28,438 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 2.07x | 3.49x |
| EPS | ₹-0.6 | ₹0.85 |
| Book Value | ₹97.23 | ₹61.31 |
| Dividend Yield | 0.09% | 0% |
Growth
| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 37.3% | -0.1% |
| EPS Growth (TTM YoY) | 68.3% | 0% |
| Qtr Sales Growth | 0% | -50.44% |
| Qtr Profit Growth | 1.33% | 263.54% |
Profitability & Leverage
| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| ROE | -4.07% | 8.6% |
| ROCE | -0.87% | 9.1% |
| Net Margin | -2.88% | -3.68% |
| Operating Margin | -0.95% | 20.01% |
| Debt to Equity | 0.57x | 0.09x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | HIKAL | PPLPHARMA |
|---|---|---|
| Promoter Holding | 68.85% | 34.8%▼ 0.06 pp |
| FII Holding | 0.99%▼ 0.44 pp | 12.52%▼ 17.66 pp |
| DII Holding | 7.24%▲ 0.04 pp | 14.57%▼ 1.04 pp |
| Public Holding | 22.93%▲ 0.41 pp | 37.63%▲ 18.62 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HIKAL and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.